Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005

Published: 2009-05-29

Articles

Thalassemia: the continued challenge

DG Nathan

https://doi.org/10.4081/hmr.v1i8.272

Published: May 29, 2009

151

PDF: 745
- PDF
Deferasirox (ICL670): from bench to bedside

DG Alberti

https://doi.org/10.4081/hmr.v1i8.273

Published: May 29, 2009

227

PDF: 662
- PDF
ICL670: clinical outcome

MD Cappellini

https://doi.org/10.4081/hmr.v1i8.274

Published: May 29, 2009

140

PDF: 300
- PDF
Treatment of aggressive lymphoma

Christer Gisselbrecht

https://doi.org/10.4081/hmr.v1i8.275

Published: May 29, 2009

136

PDF: 175
- PDF
Gemtuzumab ozogamicin

S.L. Amadori

https://doi.org/10.4081/hmr.v1i8.276

Published: May 29, 2009

153

PDF: 154
- PDF
Imatinib – an overview

MVN Deininger

https://doi.org/10.4081/hmr.v1i8.277

Published: May 29, 2009

437

PDF: 4343
- PDF
SKI-606 and beyond

DH Boschelli, F Boschelli, B Wu, F Ye, Y Wang, JM Golas, T Young, J Lucas

https://doi.org/10.4081/hmr.v1i8.278

Published: May 29, 2009

199

PDF: 428
- PDF
Follicular lymphomas

P Solal-Celigny

https://doi.org/10.4081/hmr.v1i8.279

Published: May 29, 2009

133

PDF: 230
- PDF
Anti-CD80 monoclonal antibody: galiximab

MS Czuczman

https://doi.org/10.4081/hmr.v1i8.280

Published: May 29, 2009

177

PDF: 1196
- PDF
CD30: a suitable target for immunotherapy?

Paola Borchmann

https://doi.org/10.4081/hmr.v1i8.281

Published: May 29, 2009

155

PDF: 453
- PDF
Palifermin (Kepivance™) in the treatment of mucositis

Christer Emmanouilides

https://doi.org/10.4081/hmr.v1i8.282

Published: May 29, 2009

176

PDF: 340
- PDF
Combinations of biological agents in non-Hodgkin’s lymphomas

BD Cheson

https://doi.org/10.4081/hmr.v1i8.283

Published: May 29, 2009

142

PDF: 249
- PDF
Chronic lymphocytic leukemia

MS Gentile, A Guarini, FR Mauro, R Foà

https://doi.org/10.4081/hmr.v1i8.284

Published: June 3, 2009

179

PDF: 370
- PDF
Bcr-abl peptides for chronic myeloid leukemia

MS Bocchia, M Ippoliti, MT Pirrotta, E Abruzzese, MM Trawinska, F Forconi

https://doi.org/10.4081/hmr.v1i8.285

Published: June 3, 2009

184

PDF: 434
- PDF
Tumor idyotipe as target antigen for multiple myeloma

A.B. Curti

https://doi.org/10.4081/hmr.v1i8.286

Published: June 3, 2009

139

PDF: 279
- PDF
Augmenting anti-tumor efficacy of adoptive immunotherapy with marrow infiltrating lymphocytes

I Borrello

https://doi.org/10.4081/hmr.v1i8.287

Published: June 3, 2009

131

PDF: 180
- PDF
Bortezomib therapy for refractory/relapsed multiple myeloma

M Cavo

https://doi.org/10.4081/hmr.v1i8.288

Published: June 3, 2009

165

PDF: 165
- PDF
Ubiquitin-proteasome system is a sensitive target in Ph+ leukemia

G Martinelli, D Cilloni, G Rosti, P Piccaluga, M Rondoni, C Bosi, S Paolini, F Pane, M Amabile, G Nadali, B Izzo

https://doi.org/10.4081/hmr.v1i8.289

Published: June 3, 2009

199

PDF: 257
- PDF
Bortezomib in lymphoma

A Goy

https://doi.org/10.4081/hmr.v1i8.290

Published: June 3, 2009

119

PDF: 134
- PDF
Beyond bortezomib alone: combination therapy and new strategies in targeting the proteasome

PG Richardson

https://doi.org/10.4081/hmr.v1i8.291

Published: June 3, 2009

139

PDF: 225

Untitled (): 0
- PDF
Thalidomide analogs

P Tosi, E Zamagni, D Cangini, P Tacchetti, G Perrone, M Ceccolini, M Cavo

https://doi.org/10.4081/hmr.v1i8.292

Published: June 3, 2009

185

PDF: 499
- PDF
Tipifarnib in hematologic malignancies

J-L Harousseau

https://doi.org/10.4081/hmr.v1i8.293

Published: June 3, 2009

145

PDF: 287
- PDF
Direct and indirect antitumor activity of zoledronic acid

M Massaia, S Mariani, F Pantaleoni, M Muraro, S Peola, SY Hwang, B Castella, G Matta

https://doi.org/10.4081/hmr.v1i8.294

Published: June 3, 2009

220

PDF: 286
- PDF
MLN518 – an overview

MVN Deininger

https://doi.org/10.4081/hmr.v1i8.295

Published: June 3, 2009

266

PDF: 295
- PDF
Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies

K Bhalla

https://doi.org/10.4081/hmr.v1i8.296

Published: June 3, 2009

201

PDF: 327
- PDF
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies

OA O’Connor

https://doi.org/10.4081/hmr.v1i8.297

Published: June 3, 2009

354

PDF: 457
- PDF
Anti-tumor activity of CCI-779 in relapsed mantle cell lymphoma

SM Ansell, SM Geyer, PJ Kurtin, KM Rowland, PJ Flynn, RF Morton

https://doi.org/10.4081/hmr.v1i8.298

Published: June 3, 2009

204

PDF: 399
- PDF
Gemcitabine: from solid tumor to hematology?

PL Zinzani, M Tani, V Stefoni, E Marchi, M Fina, L Alinari

https://doi.org/10.4081/hmr.v1i8.299

Published: June 3, 2009

147

PDF: 392
- PDF
The developing role of clofarabine in acute leukemias

S Faderl

https://doi.org/10.4081/hmr.v1i8.300

Published: June 3, 2009

152

PDF: 233
- PDF
Oral fludarabine

GEG Verhoef

https://doi.org/10.4081/hmr.v1i8.301

Published: June 3, 2009

128

PDF: 401
- PDF
Oxaliplatin in lymphoma

C Haioun

https://doi.org/10.4081/hmr.v1i8.302

Published: June 3, 2009

135

PDF: 838
- PDF
Lymphomatous meningitis

C Hatton

https://doi.org/10.4081/hmr.v1i8.303

Published: June 3, 2009

398

PDF: 2791
- PDF